A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects

BACKGROUND/OBJECTIVE: FKB327 is a biosimilar of the adalimumab reference product (RP). The primary objective was to assess the relative bioavailability of FKB327 after a single subcutaneous (SC) dose via prefilled syringe (PFS), auto-injector (AI), or vial with a disposable syringe (vial), in health...

Descripción completa

Detalles Bibliográficos
Autores principales: Bush, Jim, Kawakami, Kazuki, Muniz, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937755/
https://www.ncbi.nlm.nih.gov/pubmed/31888742
http://dx.doi.org/10.1186/s40360-019-0376-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937755/
https://www.ncbi.nlm.nih.gov/pubmed/31888742
http://dx.doi.org/10.1186/s40360-019-0376-9

Ejemplares similares